Roger Espinosa, MD
Interventional Cardiology · Mentor, OHNPI 1386622728
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 232 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by Novartis at 38.1% of the total. 2024 is the largest year on record at $696, 3.4 times the $206 reported in 2019. That places this record below the midpoint for interventional cardiology clinicians in OH, where the typical reported total is $4,547.
Across 232 payments — averaging $12.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- Amgen$442
- Medtronic$316
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$185
- Boehringer Ingelheim$129
- Esperion Therapeutics, Inc.$101
- plus $582 from 14 others
What the payments were for
- Food & beverage$2,81399%
- Education$221%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 137 | $1,080 |
| Amgen | 36 | $442 |
| Medtronic(2 entities) | 4 | $316 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $185 |
| Boehringer Ingelheim | 8 | $129 |
| Esperion Therapeutics, Inc. | 6 | $101 |
| AstraZeneca | 5 | $86 |
| Lexicon Pharmaceuticals, Inc. | 4 | $61 |
| Novo Nordisk | 3 | $50 |
| Impulse Dynamics (USA) Inc. | 2 | $47 |
| Pfizer | 3 | $46 |
| E.r. Squibb & Sons, L.L.C. | 2 | $44 |
| Cardiva Medical, Inc. | 1 | $41 |
| Amarin Pharma, Inc. | 2 | $38 |
| Merck | 2 | $37 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $37 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $31 |
| Johnson & Johnson | 2 | $27 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| Alnylam Pharmaceuticals Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COREVALVE EVOLUT R$152
- Octopus$129
How this compares
$2,834 in reported general payments places this provider in the 35th percentile of 256 interventional cardiology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 339 | $477,686 |
| JardianceEmpagliflozin | 128 | $169,031 |
| XareltoRivaroxaban | 134 | $168,933 |
| EntrestoSacubitril/Valsartan | 114 | $155,010 |
| Repatha SureclickEvolocumab | 77 | $86,754 |
| VascepaIcosapent Ethyl | 64 | $48,844 |
| FarxigaDapagliflozin Propanediol | 37 | $46,132 |
| LodocoColchicine | 63 | $45,720 |
| NexletolBempedoic Acid | 44 | $26,456 |
| Metoprolol Succinate | 1,315 | $18,778 |
| Rosuvastatin Calcium | 798 | $13,181 |
| NexlizetBempedoic Acid/Ezetimibe | 13 | $11,828 |
| Atorvastatin Calcium | 1,098 | $10,290 |
| Icosapent Ethyl | 13 | $6,247 |
| Ezetimibe | 220 | $5,733 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $46 | $477,686339 claims |
| Boehringer IngelheimJardiance | $129 | $169,031128 claims |
| Johnson & JohnsonXarelto | $27 | $168,933134 claims |
| NovartisEntresto | $1,080 | $155,010114 claims |
| AstraZenecaFarxiga | $86 | $46,13237 claims |
| Esperion Therapeutics, Inc.Nexletol, Nexlizet | $101 | $38,28457 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 256 interventional cardiology providers in Ohio.
Other interventional cardiology in Mentor
- Gary AnselColumbus$3.3M
- John CheathamColumbus$1.4M
- Carlos Sanchez SotoColumbus$1.1M
- Steven YakubovColumbus$907K
- Timothy HenryCincinnati$605K
- Mitchell SilverColumbus$562K
- John PhillipsColumbus$410K
- John CorlCincinnati$390K
- Santiago GarciaCincinnati$360K
- Atish MathurMansfield$291K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.